Abstract
Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.
Highlights
Cardiovascular Complications of Prostate Cancer TreatmentSpecialty section: This article was submitted to Cardiovascular and Smooth Muscle
Epidemiological studies evaluating all-cause mortality in cancer populations have revealed that almost 45% of men with prostate disease die from other reasons than cancer itself (Brown et al, 1993), and complications of anticancer treatment may be responsible for a meaningful proportion of these deaths (Beyer et al, 2005)
In terms of other CV complications, a meta-analysis was performed by Moreira et al They did not find a significant correlation between enzalutamide use and all-grade (RR 1.06, 95% CI: 0.67–1.65) or grade ≥3 (RR 0.81, 95% CI: 0.28–2.33) cardiovascular events
Summary
Specialty section: This article was submitted to Cardiovascular and Smooth Muscle. Szmit S (2020) Cardiovascular Complications of Prostate Cancer Treatment. Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. The systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. This article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
